A cascade of events, involving different biological processes, cell populations and molecular mechanisms, is involved in the pathogenesis of multiple sclerosis (MS). These processes may contribute to explain the clinical manifestations of the disease, and hence become targets of specific treatment strategies. 1 Over the past few years, pathological studies have resulted in substantial advances in the understanding of MS pathophysiology and have allowed novel disease-related mechanisms to be disclosed. Although pathology remains the gold standard, it has intrinsic limitations, including the limited number of donors available, restriction to uncommon cases and impracticality of follow-up. 2 As a consequence, there is an urgent need to develop measures capable of identifying and monitoring MS-related pathobiological processes in vivo.
PET is necessary to make the next step forward in understanding MS pathophysiology -No Paolo Preziosa , Maria A Rocca and Massimo Filippi
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Positron emission tomography (PET) 3 is based on detecting pairs of gamma rays emitted by positronemitting radionuclides (e.g. 11 C, 15 O and 18 F) located on radio-labelled molecules. Many radiotracers have been used, or are currently under investigation, for imaging the tissue concentration of different types of molecules/processes of interest in MS, both crosssectionally and in a longitudinal setting. 3 Clinical application of this technology has allowed to quantify brain metabolism (e.g. using 18 F-fluorodeoxyglucose ( 18 F-FDG)), myelin content (e.g. using 11 C-Pittsburgh Compound B ( 11 C-PIB)), neuroinflammation (e.g. using first-or second-generation radioligands on translocator protein (TSPO)) and, more recently, synaptic density (e.g. using 11 C-UCB-J). 3 As a consequence, PET can be viewed as a promising approach for monitoring MS pathophysiological substrates, such as inflammation, demyelination and remyelination, which contribute to disease progression and are among the targets of treatments. 4, 5 There are several factors that need to be considered before moving forward in the clinical use of PET for understanding MS pathophysiology. The first is related to the specificity of the radiotracers used to detect MS-related pathological processes. For example, 11 C-PIB has been proposed for quantifying myelin dynamics, since it avidly binds to myelin in the white matter, possibly through β-amyloid (Aβ) precursor protein. However, the same radiotracer is typically used to detect fibrillary Aβ deposits in patients with Alzheimer's disease and other neurodegenerative conditions. Accordingly, 11 C-PIB quantification is not myelin-specific and it might prove to be challenging, especially in older MS patients who may have comorbidities. Similarly, the use of PET with TSPO radioligands poses a number of challenges. First-generation TSPO radioligands ( 11 C-PK11195) have several non-specific binding sites in blood (platelets, monocytes and plasma proteins) and also in the healthy brain (e.g. astrocytes and blood-brain barrier). These aspecific binding sites might be disturbed in different pathological conditions, including schizophrenia. 6 To overcome these limitations, second-and third-generation TSPO radioligands have been developed, but with no clear improvement in image quality so far. There are several possible reasons for this, including a heterogeneous binding due to TSPO genetic polymorphisms, a significantly higher affinity to the blood-brain barrier and difficulties in obtaining accurate estimates of free plasma concentrations. 6 Another problematic issue is that PET abnormalities are not necessarily disease-specific. For example, microglial activity can be found not only in inflammatory demyelinating diseases such as MS, but also in several neurodegenerative conditions (e.g. Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis), traumatic brain injury and stroke. 7 The third limitation relates to the pharmacokinetics of radioligands. Ideally, the radiotracers used to investigate specific brain targets should enter the brain in adequate concentrations, should not be removed by efflux transporters and their metabolism should not interfere with quantification. 8 Although different radiolabelled molecules have been developed, 9 some of them (e.g. first-generation TSPO ligands) are characterized by a relatively poor penetration of the blood-brain barrier, which may interfere with the quantification of targets within the brain. For others, the pharmacokinetic properties still need to be fully elucidated.
An additional point that needs to be considered is that, unlike magnetic resonance imaging (MRI) where several image types (e.g. diffusion tensor MRI, magnetization transfer MRI, volumetric sequences, MR spectroscopy, etc.) can be acquired in a single session to try to unravel the pathological complexity of the disease, PET requires an a priori selection of the pathological mechanism to be investigated (e.g. demyelination, inflammation, etc). While PET can be extremely informative in this latter aspect (subjected to the limitations previously discussed), it has the major disadvantage of requiring integration with other modalities (e.g. MRI).
MS is a dynamic condition, in which different processes evolve and interact over time. Safety of any investigative technique is currently a major concern, after the alert that was recently raised regarding gadolinium retention in the body (including the brain) following the administration of MRI contrast agents, which for many years have been used for the diagnosis and monitoring of the disease. 10 PET involves exposure to ionizing radiations. Clinical PET radionuclides typically have short half-lives (from ~2 minutes for 15 O to ~110 minutes for 18 F) that limit the internal radiation dose to patients during each exposure. However, it is not clear whether radiation damage accumulated after serial application of this technique could have a negative impact on safety over the long term. Since evidence regarding the safety of serial radionuclide administration is lacking, this constrains the longitudinal application of PET for monitoring MS patient evolution in vivo.
Finally, due to the short half-lives of most positronemitting radioisotopes, the radiotracers must be produced using cyclotrons in close proximity to the PET imaging facility. This, combined with the significant cost of PET scanner purchase and maintenance, limits the number of PET scanners available and hinders its larger scale use.
In conclusion, PET imaging is a rewarding technique for investigating MS-related pathophysiological substrates in vivo. However, before applying PET more widely, it is still necessary to validate PET radioligands that are specific to different disease-related targets and to determine their pathologic relevance. In addition, optimization of PET acquisition procedures in both cross-sectional and longitudinal settings, improvements in methods for quantifying radiotracer abnormalities and studies of the possible risks from serial PET imaging are still lacking. Advanced neuroimaging provides an in-vivo exploration into diseases such as multiple sclerosis (MS). Given the ability to visualize T2-hyperintense lesions and gadolinium-enhancement, magnetic resonance imaging (MRI) has been the traditional imaging modality of choice among MS researchers and clinicians. Positron emission tomography (PET) is widely accepted within the field of oncology and more recently, actively utilized for basic research, clinical trials, and clinical management for a number of psychiatric and neurodegenerative diseases. In MS, PET has only been more actively explored over the past few years, although, [ 11 C]PK11195 (first generation TSPO ligand) was first used to evaluate MS lesions nearly 30 years ago. 1 The delay to embrace PET within the MS community is reasonable considering the complexities of PET and relative simplicity of MRI; however, as an ever-evolving field with new ligands being developed, a discussion is warranted to assess the benefits and feasibility of PET to explore pathological mechanisms of disease in MS.
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Bodini and Stankoff support the argument that PET is essential to move the field of MS forward. These authors highlight a high level of specificity gained by PET to assess activity of the innate immune system, detect early signs of neurodegeneration, and explore myelin dynamics. 2 More recently, PET ligands are being developed to explore altered synaptic function, which has gained increasing attention as a potential pathological substrate of cognitive dysfunction in MS. 3 These authors propose that PET will provide deep phenotyping of brain pathology and can be utilized to quantify an individual patients' remyelination profile. The alternative viewpoint, presented by Preziosa et al. 4 argues that most of the PET ligands, utilized for MS, have a limited cellular target and lack disease specificity. Importantly, Preziosa et al. highlight the complexity of PET, as compared to MRI, with a focus on the complicated quantification, limited safety data and poor feasibility for serial imaging.
Over the years, TSPO radioligands have improved their level of specificity, yet still remain limited by heterogeneous binding due to genetic polymorphisms. A relatively new TSPO ligand, [ 11 C]ER176, has been reported to bind all three genotypes (high, mixed, and low affinity binder), thus providing a significant advancement. 5 Furthermore, a new generation of inflammatory targets are emerging, such as purinergic receptors (P2X7, P2Y212), adenosine receptors (A2A), and cannabinoid receptor (CB2), which may provide a more specific and complex analysis of the immune response in MS as compared to TSPO ligands. 6 Hence, as ligand development continues, there lies a potential to improve the level of cellular specificity.
The lack of consensus regarding TSPO quantification has further complicated the acceptance of PET
